The United States has announced that it will impose steep tariffs on imported generic medicines starting from August 2028. The decision is part of the US government’s plan to encourage pharmaceutical companies to manufacture more medicines within the country and reduce dependence on imports. The new tariff policy is expected to begin at 100% and gradually increase, making imported generic drugs significantly more expensive.
The announcement has raised concerns among global pharmaceutical exporters, especially India, which is one of the world’s largest suppliers of affordable generic medicines to the US market. Indian pharmaceutical companies export billions of dollars’ worth of generic drugs to the United States every year. Industry experts believe that the new tariffs could increase costs for exporters and force companies to rethink their manufacturing and export strategies.
Health experts have also warned that US Generic Medicine Tariffs could lead to higher medicine prices for American consumers if lower-cost imported drugs become less available. While the US government says the move will strengthen domestic pharmaceutical manufacturing and create jobs, analysts believe it could also affect global supply chains and reshape the international generic medicine market over the coming years.